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Abstract. in order to increase our understanding of 
diabetes-related muscle weakness, we carried out a mass 
spectrometry-based proteomic analysis of skeletal muscle 
preparations from the Goto-Kakizaki rat model of type-2 
diabetes. Fluorescence difference in-gel electrophoresis was 
performed to determine potential differences in the global 
protein expression profile of muscle extracts. Besides changes 
in contractile proteins and metabolic enzymes, the abun-
dance of the small stress proteins αB-crystallin and Hsp27 
was significantly increased. The up-regulation of the low-
molecular-mass heat shock protein Hsp27 was confirmed by 
an alternative fluorescent staining method of two-dimensional 
gels and immunoblotting. The observed protein alterations 
in the cellular stress response, distinct metabolic pathways, 
regulatory mechanisms and the contractile apparatus might 
be directly or indirectly associated with peripheral resistance 
to insulin signalling, making these newly identified muscle 
proteins potential biomarkers of type-2 diabetes. increased 
levels of molecular chaperones suggest considerably enhanced 
cellular stress levels in diabetic muscle fibres.
Introduction
The application of gel electrophoresis-based proteomics 
in diabetes research is a fast growing field (1), including 
the proteomic analysis of diabetic skeletal muscle tissues 
(2-7). Since diabetes is increasingly prevalent in the general 
population, research into the complex pathophysiological 
mechanisms that underlie abnormal signaling in crucial target 
organs, such as skeletal muscle, is of central importance 
(8-10). It is now clear that type-2 diabetes mellitus represents 
a group of heterogeneous disorders with abnormal expres-
sion patterns in various genes and protein products (11-13). 
Peripheral insulin resistance in the liver, adipose tissue and 
muscles, as well as impaired pancreatic β-cell functioning, are 
the principal features of type-2 diabetes (11). The worldwide 
incidence of type-2 diabetes is dramatically increasing (14) and 
it has been estimated that the incidence of diabetes will rise to 
a staggering 4.4% by the year 2030, with 366 million affected 
patients (15). Importantly, type-2 diabetes is associated with a 
loss of skeletal muscle mass and contractile strength (16-19) 
warranting detailed investigations into diabetes-related 
muscle weakness (20). In this respect, large-scale biochemical 
approaches, such as gel electrophoresis-based proteomics, are 
ideal analytical tools for an unbiased identification of novel 
protein factors that are associated with abnormal functioning 
in diabetic fibres.
High-resolution two-dimensional gel electrophoresis 
has long been established as one of the most powerful 
biochemical techniques for the comparative analysis of large 
protein complements (21-23). The more recent combination of 
advanced gel electrophoretic methods with mass spectrometry 
has further reinforced the central importance of gel electro-
phoretic techniques for analytical protein chemistry (24-26). 
The unprecedented advancements of mass spectrometric 
methods for the swift identification of minute amounts of 
protein (27) and the emergence of high-throughput proteomics 
as a major new field in modern biochemistry (28) have opened 
unparalleled opportunities for the in-depth analysis of complex 
pathological processes. However, a major obstacle for the inclu-
sive cataloging of large and diverse protein complements is the 
dynamic concentration range of protein species within a given 
class of cells or tissues. Since different staining techniques 
used in two-dimensional gel electrophoresis visualize varied 
dynamic expression ranges, protein labeling may considerably 
influence proteomic identification protocols. Here, we have 
used fluorescence difference in-gel electrophoresis (DIGE) 
for the determination of potential expression changes in the 
soluble proteome from normal Wistar rat muscle versus type-2 
diabetic Goto-Kakizaki (GK) rat muscle. The GK rat is an 
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established animal model of non-obese type-2 diabetes (29) 
that exhibits peripheral insulin resistance (30) and numerous 
molecular and cellular abnormalities due to its diabetic status 
(30-32), including abnormal skeletal muscle functions (33-38). 
our comparative mass spectrometry-based proteomic 
analysis revealed a moderately disturbed protein expression 
pattern in diabetic muscle fibres. Mass spectrometry identi-
fied 15 distinct two-dimensional protein spots with an altered 
abundance in diabetic muscle tissue preparations, using 
analytical DIGE gels with a pH 3-10 range. Besides altered 
expression patterns in various contractile and metabolic 
muscle proteins, a striking increase in two heat shock proteins 
(Hsp), αB-crystallin and Hsp27, was established by densito-
metric scanning and mass spectrometry. Muscle-associated 
Hsps protect contractile fibres during hyperthermia, hypoxic 
insult, ischemic damage, extensive periods of exercise, trau-
matic injury and in numerous neuromuscular diseases (39). 
Hsps of low molecular mass are specifically induced during 
muscle injury (40), whereby their main cytoprotective func-
tions include the prevention of deleterious protein aggregation 
and the modulation of intermediate filament assembly (41). 
Small Hsps are characterized by a conserved 90-residue 
carboxy-terminal sequence, the α-crystallin domain (42). 
The abundance of these small cytoprotective chaperones 
appears to be increased in GK muscle tissue. Hence, diabetes-
related changes in the cellular stress response, the contractile 
machinery, metabolic pathways and various regulatory mech-
anisms are possibly linked to peripheral insulin resistance in 
skeletal muscles. in the future, these novel signature molecules 
might be helpful for the establishment of a comprehensive 
biomarker signature of type-2 diabetes mellitus.
Materials and methods
Materials. electrophoretic buffers, protein assay reagents 
and protein molecular weight ladders were obtained from 
Bio-Rad laboratories (Hemel Hempstead, Hertfordshire, 
UK). Ultrapure Protogel acrylamide stock solutions and 
nitrocellulose membranes were from national diagnostics 
(atlanta, Ga, USa) and Millipore (Bedford, Ma, USa), 
respectively. fluorescent cyDyes, imobiline pH gradient 
IPG dry strips, ampholytes, cover fluid and acetonitrile 
were purchased from amersham Bioscience/GE Healthcare 
(little chalfont, Bucks, UK). Sequencing grade-modified 
trypsin, used for the peptide mass spectrometric identifica-
tion of skeletal muscle proteins, was obtained from Promega 
(Madison, WI, USa). lc-MS chromasolv water and formic 
acid were purchased from fluka (Milwaukee, WI, USa). 
coomassie Brilliant Blue G-250 dye was from Thermo 
fisher Scientific (Waltham, Ma, USa). Primary antibodies 
were obtained from abcam ltd. (cambridge, UK) (ab12351 
to Hsp27; ab36329 to isocitrate dehydrogenase; ab88184 to 
myozenin; ab16834 to superoxide dismutase; ab89511 to actin 
capping-protein; and ab54913 to carbonic anhydrase ca3). 
Secondary peroxidase-conjugated antibodies were purchased 
from chemicon International (Temecula, ca, USa). Protease 
inhibitors and chemiluminescence blotting substrate were 
obtained from Roche Diagnostics (Mannheim, Germany). all 
other analytical-grade chemicals were purchased from Sigma 
chemical company (Dorset, UK).
Diabetic animal model. For the comparative proteomic anal-
ysis of normal versus diabetic muscle tissue, normal Wistar 
rats and the spontaneous diabetic Goto-Kakizaki (GK) rat 
were used in this study. The GK rat is an established model of 
non-obese type-2 diabetes (29-32). Rats were purchased from 
Taconic M&B ltd. animal Suppliers (Ry, Denmark). The 
total soluble proteome was extracted from the gastrocnemius 
muscles of 9-week-old normal rats and age-matched GK rats. 
The diabetic status of the cohort of GK rats employed in this 
study has previously been described in detail (37).
Preparation of muscle extract. Gastrocnemius muscle samples 
from normal and GK rats with a wet weight of 200 mg were 
quick-frozen in liquid nitrogen and then ground into a fine 
powder using a mortar and pestle. The muscle powder was 
transferred into 1 ml lysis buffer containing 2% (v/v) pH 3-10 
ampholytes, 7 M urea, 2 M thiourea, 4% (w/v) cHaPS and 
100 mM dithiothreitol.  a freshly prepared protease inhibitor 
cocktail was added to the buffer to prevent proteolytic degra-
dation of sensitive muscle proteins (5). The suspension was 
incubated for 3 h at room temperature and then centrifuged 
at 14,000 x g for 20 min at 4˚c. The Bradford dye-binding 
method was used to determine the protein concentration of 
the final extracts from normal versus GK muscle tissue (43).
Gel electrophoretic analysis. Total crude skeletal muscle 
extracts of normal (n=4) and diabetic (n=4) muscle tissues were 
separated in the first dimension by isoelectric focusing and in 
the second dimensional by standard sodium dodecyl sulphate 
polyacrylamide gel electrophoresis, as previously described 
by our laboratory (44-46). IPG strips were rehydrated for 12 h 
in a buffer consisting of 7 M urea, 2 M thiourea, 4% (w/v) 
cHaPS, 1.2% deStreak and 2% (v/v) pH 3-10 ampholytes. 
The buffer system contained 400 µg of muscle protein. The 
first-dimension protein separation was conducted using IPG 
strips on an amersham IPGphor IEf system (amersham 
Bioscience/GE Healthcare) following the protocol previously 
described in detail (44). The first dimension strips were further 
subjected to reduction and alkylation (45) before separation 
in the second-dimension on 12.5% (w/v) slab gels using an 
amersham Ettan DalT-Twelve system (46). 
Protein visualisation. for DIGE analysis, cy3 and cy5 
dyes were reconstituted as a stock solution of 1 mM in 
fresh dimethylformamide. The stock solution was diluted 
to a working solution of 0.2 mM prior to protein labelling. 
Individual samples (50 µg protein) were minimally labelled 
with 200 pmols of cy3 working solution (47). a pooled 
sample consisting of equal quantities of protein from all 
replicates used in the experiment were labelled at a ratio of 
200 pmol of cy5 working solution to 50 µg of muscle protein. 
all samples were labelled with the appropriate amount of dye 
at pH 8.5 and then incubated on ice in the dark for 30 min. 
The reaction was quenched by 10 mM lysine for 10 min on 
ice in the dark. during the subsequent rehydration step, 
samples were loaded onto iPG strips with an equal volume of 
2X sample buffer (7 M urea, 2 M thiourea, 65 mM cHaPS, 
2% ampholytes and 2% dithiothreitol). Slab gels were stained 
for total protein with coomassie Brilliant Blue or ruthenium 
bathophenanthroline disulfonate (RuBPs). a stock solution 
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of RuBPs dye was prepared as described by Rabilloud et al. 
(48). Two-dimensional gels were fixed overnight in 30% (v/v) 
ethanol and 10% (v/v) acetic acid and subsequently washed 
4 times for 30 min in 20% (v/v) ethanol to remove traces of 
acetic acid (49). The ruthenium fluorophore was then applied 
to the gels by adding 10 ml of the freshly synthesized dye to 
1 litre of 20% (v/v) ethanol in the dark. Gels were incubated for 
6 h in the staining solution. labelled gels were then destained 
in 40% (v/v) ethanol and 10% (v/v) acetic acid. Reference gels 
for spot picking were stained with coomassie Brilliant Blue 
(46). Gel images were analysed using Progenesis SameSpots 
software version 3.2.3 from nonlinear Dynamics (newcastle 
upon Tyne, UK).
Mass spectrometric identification of skeletal muscle proteins. 
The mass spectrometric analysis of peptide mixtures derived 
from distinct two-dimensional spots was carried out on 
a Model 6430 Ion Trap lc/MS apparatus from agilent 
Technologies (Santa clara, ca, USa). The excision of protein 
spots and subsequent washing, destaining and digestion steps 
were preformed by a previously optimised method (44-46). 
Trypsination-generated peptides were recovered from super-
natants of digested gel plugs and samples dried through 
vacuum centrifugation. The resulting peptides were resus-
pended in 10 µl of MS-grade ddH2O and 0.1% (w/v) formic 
acid for identification by ion trap lc-MS analysis. Separation 
of peptides was performed with a nano flow agilent 1200 
series system, equipped with a Zorbax 300SB-c 185 mm, 
4 mm 40 nl pre-column and a Zorbax 300SB-c 185 mm, 
43 mm x 75 µm analytical reversed- phase column using 
HPlc-chip technology (50). Mobile phases utilized were a, 
0.1% formic acid; B, 50% acetonitrile and 0.1% formic acid. 
Samples (5 µl) were loaded into the enrichment at a capillary 
flow rate set to 2 µl/min with a mix of a and B at a ratio of 
19:1. Tryptic peptides were eluted with a linear gradient of 
10-90% solvent B over 2 µl/min with a constant nano pump 
flow of 0.6 ml/min. a 1 min post time of solvent a was used 
to remove sample carry over. The capillary voltage was set to 
1700 v. The flow and the temperature of the drying gas were 
4 µl/min and 300˚c, respectively (5). Database searches were 
carried out with Spectrum Mill Work Bench or Mascot MS/
MS Ion search (Matrix Science, london, UK).
Immunoblot analysis. To verify changes in the abundance 
of select proteins in GK muscle preparations, immunoblot-
ting was carried as previously described in detail (37). Gels 
were transferred to nitrocellulose and blocked with a milk 
protein solution consisting of 5% (w/v) fat-free milk powder 
in 0.9% (w/v) nacl, 50 mM sodium phosphate, pH 7.4 for 
1 h. Subsequently, membranes were incubated overnight 
with sufficiently diluted primary antibody, washed and then 
incubated for 1 h with secondary peroxidase-conjugated 
antibodies, diluted in blocking solution. The visualization of 
immuno-decorated bands was carried out by the enhanced 
chemiluminescence method using blotting substrate from 
Roche Diagnostics (Mannheim, Germany). Densitometric 
scanning of immunoblots was performed on a Molecular 
Dynamics 300S computing densitometer (Sunnyvale, ca, 
USa) with ImageJ (nIH, USa) and GraphPad Prism (San 
Diego, ca, USa) software.
Results
Proteomic analysis of diabetic GK muscle extracts. difference 
in-gel electrophoresis (DIGE) represents an excellent analytical 
tool for large-scale proteomic surveys  (51-53), and this method 
was applied here for the comparative analysis of normal versus 
diabetic muscle extracts. With the help of a Typhoon Trio vari-
able imager and Progenesis 2-D analysis software, 15 protein 
species out of 1734 detectable two-dimensional spots were 
found to be differentially expressed. representative cy3 and 
cy5 gels with electrophoretically separated proteins from 
normal versus diabetic muscle tissue are shown for the pH 3-10 
range in Fig. 1a-d. The protein spot patterns of normal versus 
pathological preparations were relatively comparable. However, 
the detailed densitometric analysis of Wistar rat versus GK rat 
muscle tissue identified distinct changes in a variety of protein 
species. a representative diGe master gel of GK rat skeletal 
muscle preparations employed for the mass spectrometric 
identification of proteins with a diabetes-related differen-
tial expression pattern is shown in Fig. 1e. Skeletal muscle 
proteins that exhibited a more than 2-fold change in expression 
levels are marked by circles and are numbered 1 to 15. Proteins 
species with a changed concentration in GK gastrocnemius 
muscle ranged in molecular mass from 16 kDa (hemoglobin) 
to 224 kDa (myosin heavy chain) and covered a pI-range 
from pI 4.1 (troponin) to pI 8.9 (bisphosphoglycerate mutase). 
an increased abundance was found in the case of 10 skeletal 
muscle-associated proteins, and 5 proteins were shown to be 
decreased in their concentration.
Proteomic profile of diabetic skeletal muscle tissue.  a list 
of the 15 DIGE-identified muscle proteins that exhibited a 
drastically altered expression level in the non-obese diabetic 
GK rat is shown in Table i. listed are the names of the iden-
tified proteins, their international protein accession number, 
pI-values, their relative molecular masses, the number of 
matched peptide sequences, percentage sequence coverage, 
Mascot scores, and fold-change of individual proteins affected 
in diabetic muscle tissue. The identified muscle proteins were 
found to be mostly associated with the contractile apparatus, 
muscle metabolism, metabolite transportation and the cellular 
stress response. The numbering of spots in the diGe-labeled 
master gel of Fig. 1e correlates with the listing of mass 
spectrometry-identified protein species in Table I. The protein 
with the highest decrease in concentration was identified as 
bisphosphoglycerate mutase, and that with the highest increase 
in abundance shown to be the fast 1f-isoform of myosin light 
chain. Muscle proteins with a drastic decrease were found to 
be bisphosphoglycerate mutase (spot 1), myosin heavy chain 4 
(spot 2), troponin c (spot 3), Tip1 protein (spot 4) and hemo-
globin (spot 5). In contrast, muscle proteins with an increased 
expression in diabetic muscle tissue were identified as fast 
troponin T (spots 6 and 11), tropomyosin (spot 7), slow myosin 
light chain 3 (spot 8), fast myosin light chain 1f (spots 9 
and 15), Hsp27 (spot 10), αB-crystallin (spot 12), myozenin 
(spot 13) and myoglobin (spot 14).
RuBPs analysis of Hsp27 in GK muscle extracts. To verify the 
increased levels of the low-molecular-mass molecular chap-
erone Hsp27 in GK muscle, as revealed by DIGE analysis, the 
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fluorescent dye RuBPs was employed for labeling electropho-
retically separated muscle proteins. as illustrated in Fig. 1F, a 
protein spot with an approximate pI-value of 6 and a relative 
molecular mass of 27 kDa was identified as Hsp27/HspB1. The 
mass spectrometric fingerprint of the RuBPs-stained Hsp27 
protein spot is shown in Fig. 1G and illustrates 60% coverage 
of matched peptides. Thus, the densitometric analyses of 
two independent fluorescent labeling approaches agreed and 
clearly demonstrated a drastic increase in the small stress 
protein Hsp27. 
Immunoblot analysis of GK muscle extracts. in order to 
correlate the findings of the DIGE-based study described 
here and a previously published proteomic survey of GK 
muscle using coomassie Brilliant Blue (5), an immunoblot 
analysis was carried out with normal versus GK preparations. 
Both the drastic diabetes-related increase in Hsp27 and the 
actin binding-protein myozenin were clearly confirmed by 
immunoblotting (fig. 2a, B and G). The previously estab-
lished drastic decrease in carbonic anhydrase isoform ca3 
and moderate increase in isocitrate dehydrogenase, cu/Zn 
superoxide dismutase and actin capping-protein were also 
confirmed (fig. 2c-f and H). Hence, immunoblotting veri-
fied the increased abundance of Hsp27 in diabetic GK muscle 
tissue and the differential expression pattern of other novel 
muscle-associated marker proteins of type-2 diabetes.
figure 1. Proteomic profiling of diabetic rat GK skeletal muscle using fluorescent DIGE analysis and RuBPs staining. crude total muscle extracts from normal 
and Goto-Kakizaki (GK) gastrocnemius muscle tissue were separated in the first dimension by isolelectric focusing and in the second dimension by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. Shown are cy3-labeled control samples (a), cy3-labeled diabetic GK samples (c) and cy5-labeled pooled 
standards (B, D). a DIGE master gel with a pH 3-10 range is shown in panel (E). Identified muscle proteins are marked by circles and are numbered 1 to 15. 
See Table i for a detailed listing of protein species that exhibited a diabetes-related alteration in their expression levels. To verify the changed abundance in 
the molecular chaperone Hsp27 (spot no. 10), fluorescent RuBPs staining was used (f). The two-dimensioanl spot representing Hsp27 is marked by a circle. 
The pH-values of the first dimension gel system and molecular mass standards (in kDa) of the second dimension are indicated on the top and on the left of 
panels (E, f), respectively. The mass spectrometric fingerprint of Hsp27 is shown in panel (G).
  A   B   C   D
  G
  E   F
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Discussion
The GK rat is an established animal model of non-obese 
type-2 diabetes. importantly, these animals are spontaneously 
diabetic (29) and clearly exhibit increased blood glucose 
levels without significant alterations in non-fasting plasma 
insulin levels and body weight (30-33). We chose GK muscle 
tissues because they represent a suitable model system for 
studying fundamental mechanisms of type-2 diabetes without 
potentially complicating factors due to obesity. it is important 
Figure 2. immunoblot analysis of diabetic rat GK skeletal muscle. Shown are representative immunoblots with expanded views of immuno-decorated bands. 
Immunoblotting was performed with antibodies to the molecular chaperone Hsp27 (a), the actin binding protein myozenin (B), the enzyme isocitrate dehy-
drogenase (c; IcDH), the enzyme cu/Zn superoxide dismutase (D; SOD), actin capping-protein (E; cP) and the enzyme carbonic anhydrase isoform ca3 
(f). Shown is the graphical presentation of the statistical evaluation of immuno-decoration using antibodies to Hsp27 (G) and carbonic anhydrase ca3 (H). 
The comparative blotting was statistically evaluated using an unpaired Student's t-test (n=5; *p<0.05; **p<0.01). lanes 1 and 2 represent normal and diabetic 
muscle extracts from control and GK rats, respectively. 
Table I. DIGE-identified proteins with a changed abundance in diabetic GK muscle extracts.
Spot Protein name accession iso-electric Molecular Matched coverage Mascot Fold
no.  no. point pI mass (kDa) peptides (%) score change
1 Bisphospho glycerate mutase gi|8393948| 8.9 28.911 16 43 185 -3.3
2 Myosin heavy chain 4, skeletal muscle gi|106879208| 5.6 223.669 17 7 181 -2.4
3 Troponin c, type 2 gi|82654194| 4.1 18.142 19 65 482 -2.2
4 Tip1 protein  gi|38512111| 7.1 27.228 26 81 459 -2.1
5 β-hemoglobin gi|204570| 7.9 16.099 3 28 141 -2.0
6 Troponin T, fast  gi|136385| 6.2 30.732 2 11 78 2.0
7 Tropomyosin 2, β gi|11875203| 4.7 32.933 16 33 361 2.1
8 Myosin, light chain 3, slow gi|6981240| 5.0 22.258 16 75 288 2.1
9 Myosin light chain 1f, fast gi|117676401| 4.9 20.782 9 51 113 2.1
10 Heat shock protein Hsp27 gi|1170367| 6.1 22.937 11 60 119 2.4
11 Troponin T, fast  gi|136385| 6.2 30.732 4 15 86 2.4
12 αB-crystallin gi|57580| 8.8 19.945 13 55 204 2.5
13 Myozenin  gi|157819165| 8.6 31.379 2 11 109 2.6
14 Myoglobin gi|11024650| 7.8 17.204 2 21 98 3.2
15 Myosin light chain 1f, fast gi|117676401| 4.9 20.782 6 31 125 3.4
  A   B   C
  D
  G   H
  E   F
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to stress that no animal model represents a perfect replica 
of all pathobiochemical aspects seen in a highly complex 
human pathology. However, if one keeps in mind species-
specific differences, findings from animal model proteomics 
can be extrapolated to the human situation (54). Ideally, a 
diabetic animal model should closely resemble the etiology 
of the human disease in onset, progression, complexity and 
severity, as well as develop all or most of the multi-factorial 
aspects usually observed in end-stage human pathology. a 
good model system should also mimic the basic mechanisms 
of human physiology and metabolism that are important for 
the development of diabetic side effects. it is therefore critical 
to choose the right age range of pathological GK tissues to 
study diabetic dysfunctions at a prominent stage of disease 
progression. it was previously reported that cellular defects 
in insulin secretion and peripheral insulin resistance occur by 
4 weeks of age in the GK rat (30,31). The proteomic profiling 
of diabetic muscle described here was therefore performed 
with 9-week-old animals that clearly exhibited elevated levels 
of glucose (37).
diabetic GK skeletal muscles are characterized by an inhi-
bition of insulin receptor auto-phosphorylation (33), impaired 
activities of numerous key insulin signaling intermediates 
(32-34), a diminished recruitment of glucose transporter 
GluT4 molecules possibly linked to membrane cytoskeletal 
defects in the dystrophin-dystroglycan complex (20,37), 
drastically lowered mitochondrial enzyme activities (38) and 
a reduced percentage of oxidative fibres (35). These findings 
demonstrate chronically impaired insulin signaling in GK 
skeletal muscles making them a suitable model system to 
determine global changes in the protein expression pattern due 
to diabetic complications. The proteomic analysis presented 
here has clearly shown increased levels of the small chaperone 
Hsp27, also termed HspB1 (42), in GK muscle preparations. 
Importantly, results of our DIGE analysis were confirmed 
by fluorescence RuBPs labeling and immunoblotting. This 
report therefore confirms the findings of a previous proteomic 
characterization of GK muscle using coomassie Brilliant 
Blue staining (5) and suggests a considerable up-regulation 
of specific low-molecular-mass chaperones in diabetic muscle 
tissue. The main cytoprotective functions of small Hsps include 
the modulation of intermediate filament assembly and the 
prevention of deleterious protein aggregation (41). In addition, 
increased levels of cu-Zn superoxide dismutase (55) suggest 
a critical need of diabetic muscles for an up-regulation of the 
anti-oxidant defense system. Thus, in analogy to dystrophic 
and aged skeletal muscles (45,56), contractile tissue seems to 
be associated with considerable levels of cellular stress due to 
type-2 diabetes.
in addition, the proteomic screening of GK muscle tissue 
also revealed protein alterations in the contractile apparatus 
and metabolic elements, suggesting a generally perturbed 
protein expression patterns due to diabetic side effects. These 
diabetes-related changes might be directly or indirectly asso-
ciated with peripheral insulin resistance. The status of these 
newly identified markers of type-2 diabetes needs to be veri-
fied by detailed biochemical, physiological and cell biological 
characterizations in order to establish a reliable biomarker 
signature of diabetes mellitus. differential expression patterns 
of crucial contractile proteins agree with the concept of 
impaired muscle strength in diabetes (16-19). The pattern 
of altered abundance in contractile and regulatory elements 
does not indicate a fibre type-specific shift. On the one hand, 
protein spots representing myosin heavy chain 4 and troponin 
c were decreased in GK muscle. on the other hand, crucial 
contractile elements such as slow and fast isoforms of myosin 
light chain, myozenin and fast troponin T were found to be 
increased in diabetic preparations. Thus, in agreement with 
previous studies that have shown marked pathophysiological 
alterations in GK rat tissues (5,7,30-38) and diabetic specimens 
from patients (2-4,6,15-18), the results presented here confirm 
the drastic effects of type-2 diabetes on voluntary contractile 
fibres. 
In the field of neuromuscular pathology, there is an urgent 
need for the establishment of disease-specific biomarker 
signatures that can be used to differentiate between common 
changes due to general fibre degeneration versus patho-
biochemical mechanisms that are unique to a particular 
muscular disorder. various proteomic profiling programmes 
have been initiated to identify novel signature molecules of 
muscular atrophy, muscular dystrophy, muscle transformation 
and age-related muscle wasting (57). In our experience, it is 
advisable to initially carry out small-scale pilot experiments 
to determine the general suitability of different protein dyes 
for specific proteomic applications. Thus, besides taking into 
account differing electrophoretic mobilities of soluble versus 
integral proteins, it is also important to keep in mind the 
affinity of diverse classes of proteins for different dye staining 
protocols. Here, we have shown that the DIGE method and 
the fluorescent dye RuBPs are highly suitable to determine 
protein alterations in the non-obese diabetic GK gastrocne-
mius muscle. In conclusion, the proteomic identification of 
the biomarker signature of diabetic effects on skeletal muscle 
may be useful for complementing future physiological and 
biochemical investigations into the molecular mechanisms 
of peripheral insulin resistance (58). The newly established 
tissue-specific combination of disease markers might also 
be exploitable in the evaluation of the effects of novel drug 
regimes, gene therapy approaches or cell-based therapies 
for counter-acting serious side effects of type-2 diabetes in 
peripheral tissues.
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